What is HC Wainwright’s Forecast for PVLA FY2029 Earnings?

by · The Cerbat Gem

Palvella Therapeutics (NASDAQ:PVLA – Free Report) – HC Wainwright issued their FY2029 earnings estimates for shares of Palvella Therapeutics in a report released on Friday, January 3rd. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.69) per share for the year. HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock.

Separately, Cantor Fitzgerald initiated coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock.

View Our Latest Stock Report on Palvella Therapeutics

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock opened at $14.73 on Monday. The firm has a market cap of $19.44 million, a price-to-earnings ratio of -1.22 and a beta of 0.67. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $22.32.

Insider Activity at Palvella Therapeutics

In other news, Director George M. Jenkins purchased 4,000 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was bought at an average cost of $12.93 per share, for a total transaction of $51,720.00. Following the completion of the purchase, the director now directly owns 180,671 shares of the company’s stock, valued at $2,336,076.03. The trade was a 2.26 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.39% of the stock is owned by insiders.

See Also